A 12week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of concentrated powder of Oenanthe javanica on improving liver function.

A 12 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of concentrated powder of Oenanthe javanica on improving liver function.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000820

Enrollment

Registered

2013-08-13

Start date

2013-07-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : intake of intervention powder or placebo during 12 weeks of research period: 3 capsules after evening meals with water.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Between more than the normal value of normal AST, ALT, and GGT and less than 3 times of normal AST, ALT, and GGT level (AST;39-114, ALT;44-129, and GGT:76-225 at screening period)

Exclusion criteria

Exclusion criteria: 1. patients who are taking treatment due to alcohol abuse, alcohol-related disease, heart disease and CNS disease 2. liver cirrhosis or hepatoma on sonography 3. viral hepatitis 4. HBs Ag(+), or HCV Ab(+) 5. sujects who took medication of liver mediated metabolism such ad INH, valproic acid, tetracycline, allopurinol, ibuprofen, phenytoin phenelzin, sertraline, naproxen, diclofenac, and any drug affecting liver toxicity within 4 weeks before enroll. 6. subjects who are taking steroid or sex hormone within 4 weeks before enroll. 7. intractable hypertension(over 160/100mg) or DM with more than 180mg/dl of fasting glucose . 8. Newly taking antilipidemic drug of DM medication wihtin 3 months before enroll. 9. during pregnancy or plan of pregnancy 10. subjects who are registered on the other clinical research within 1 month before enroll. 11. subjects pressumed as not appropriate by researchers.

Design outcomes

Primary

Measure	Time frame
Change of AST(GOT);Change of ALT(GPT);Change of and ?-GTP	—

Secondary

Measure	Time frame
change of ratio of AST/ALT; change of MFS scores ; change of total cholesterol, LDL and HDL cholesterol	—

Countries

Korea, Republic of

Contacts

Public ContactKang Suk

Hallym University Medical Center

Outcome results